Director's Dealing • Oct 21, 2025
Director's Dealing
Open in ViewerOpens in native device viewer

Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
|---|---|---|---|---|---|---|
| Analytical | Bioventures | S.C.A | (RCS | B89265) | ||
| a) | Name | 23, Va Fleuri, L-1526 Luxembourg |
| 2. | Reason for the notification | |||
|---|---|---|---|---|
| a) | Position / status | Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin |
||
| b) | Initial notification / amendment | Initial |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
|---|---|---|---|
| a) | Name | Eurofins Scientific S.E. | |
| b) | LEI | 529900JEHFM47DYY3S57 |
| 4. | Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|---|---|---|---|
| a) | Description of the financial instrument, type of instrument |
Share | |
| Identification code | ISIN: FR0014000MR3 | ||
| Acquisition of shares | |||
| b) | Nature of the transaction | ||
| Price(s) | Volume(s) | ||
| c) | Price(s) and volume(s) | EUR 62.063600 | 3000 |
| Aggregated information | |||
| — Aggregated volume | 3000 | ||
| d) | — Price | EUR 186,190.80 | |
| e) | Date of the transaction | 2025-10-15 | |
| f) | Place of the transaction | XPAR |
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
|---|---|---|---|---|---|---|
| Analytical | Bioventures | S.C.A | (RCS | B89265) | ||
| a) | Name | 23, Va Fleuri, L-1526 Luxembourg |
| 2. | Reason for the notification | |
|---|---|---|
| a) | Position / status | Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin |
| b) | Initial notification / amendment | Initial |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
|---|---|---|---|
| a) | Name Eurofins Scientific S.E. |
||
| b) | LEI | 529900JEHFM47DYY3S57 |
| 4. | Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|---|---|---|---|
| a) | Description of the financial instrument, type of instrument |
Share | |
| Identification code | ISIN: FR0014000MR3 | ||
| Acquisition of shares | |||
| b) | Nature of the transaction | ||
| Price(s) | Volume(s) | ||
| c) | Price(s) and volume(s) | EUR 62.376500 | 3000 |
| Aggregated information | |||
| — Aggregated volume | 3000 | ||
| d) | — Price | EUR 187,129.50 | |
| e) | Date of the transaction | 2025-10-16 | |
| f) | Place of the transaction | XPAR |
Eurofins Scientific 2/4 October 2025
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
|---|---|---|---|---|---|---|
| Analytical | Bioventures | S.C.A | (RCS | B89265) | ||
| a) | Name | 23, Va Fleuri, L-1526 Luxembourg |
| 2. | Reason for the notification | |
|---|---|---|
| a) | Position / status | Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin |
| b) | Initial notification / amendment | Initial |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
|---|---|---|---|
| a) | Name | Eurofins Scientific S.E. | |
| b) | LEI | 529900JEHFM47DYY3S57 |
| 4. | Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|---|---|---|---|
| a) | Description of the financial instrument, type of instrument |
Share | |
| Identification code | ISIN: FR0014000MR3 | ||
| Acquisition of shares | |||
| b) | Nature of the transaction | ||
| Price(s) | Volume(s) | ||
| c) | Price(s) and volume(s) | EUR 62.3724 | 3000 |
| Aggregated information | |||
| — Aggregated volume | 3000 | ||
| d) | — Price | EUR 187,117.20 | |
| e) | Date of the transaction | 2025-10-17 | |
| f) | Place of the transaction | XPAR |
Eurofins Scientific 3/4 October 2025
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
|---|---|---|---|---|---|---|
| Analytical | Bioventures | S.C.A | (RCS | B89265) | ||
| a) | Name | 23, Va Fleuri, L-1526 Luxembourg |
| 2. | Reason for the notification | |
|---|---|---|
| a) | Position / status | Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin |
| b) | Initial notification / amendment | Initial |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
|---|---|---|---|
| a) | Name | Eurofins Scientific S.E. | |
| b) | LEI | 529900JEHFM47DYY3S57 |
| 4. | Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|---|---|---|---|
| a) | Description of the financial instrument, type of instrument |
Share | |
| Identification code | ISIN: FR0014000MR3 | ||
| Acquisition of shares | |||
| b) | Nature of the transaction | ||
| Price(s) | Volume(s) | ||
| c) | Price(s) and volume(s) | EUR 63.504300 | 3000 |
| Aggregated information | |||
| — Aggregated volume | 3000 | ||
| d) | — Price | EUR 190,512.90 | |
| e) | Date of the transaction | 2025-10-20 | |
| f) | Place of the transaction | XPAR |
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620 E-mail: [email protected]urofinseu.com
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With ca. 63,000 staff across a network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods.
Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.
Have a question? We'll get back to you promptly.